It is made available under a CC-BY-NC 4.0 International license .

1	Use of the test-negative design to estimate the protective effect of a scalar
2	immune measure: A simulation analysis
3	Authors: Ziyuan Zhang <sup>1</sup> , Christopher Brian Boyer <sup>1</sup> , Marc Lipsitch <sup>1,2*</sup>
4	Affiliations:
5	<sup>1</sup> Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H.
6	Chan School of Public Health, Boston, Massachusetts, USA
7	<sup>2</sup> Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public
8	Health, Boston, Massachusetts, USA
9	* Correspondence: Marc Lipsitch, DPhil, Center for Communicable Disease Dynamics,
10	Department of Epidemiology, Harvard T.H. Chan School of Public Health, 677 Huntington
11	Avenue, Boston, MA 02115, USA. (mlipsitc@hsph.harvard.edu).

It is made available under a CC-BY-NC 4.0 International license .

# 12 Abstract

Background: The relationship between antibody levels (more generally, a scalar measure of 13 14 immune protection) at the time of exposure to infection (so-called exposure-proximal correlates of protection) and the risk of infection given exposure is of central interest in evaluating the 15 16 evolution of immune protection conferred by prior infection and/or vaccination. A version of the 17 test-negative study design (TND), adapted from vaccine effectiveness studies, has been used to 18 assess this relationship. However, the conditions under which such a study identifies the 19 relationship between immune measurements and protection have not been defined. **Objective**: To evaluate the conditions for TNDs to estimate the relationship between antibody 20 21 levels or a similar scalar measurement of immunity (hereafter exposure-proximal correlates of 22 protection, COP) and the relative incidence rate of infection given exposure. 23 **Method**: Individual-based transmission models, linking infection risk linearly and nonlinearly 24 with COP value and accounting for waning immunity post-vaccination and -infection, were used. 25 Simulations were performed of a TND with sampling on predetermined dates. Data from either 26 one or multiple simulation days were analyzed using logistic regression and generalized additive 27 models. **Result**: A correctly specified logistic regression model provided an unbiased estimate of the 28 29 effectiveness of specific COP levels (analogous to vaccine effectiveness). Aggregating data 30 across different simulation dates with incidence-density sampling also provided reliable 31 estimates of protection. When, as is generally the case, the functional form relating COP level to 32 protection is unknown, generalized additive models offer a more flexible alternative to 33 traditional logistic regression approaches.

- 34 **Conclusion**: A TND can validly estimate the relative effect of an immune COP at the time of
- 35 exposure on the incidence rate of infection via logistic regression if the functional form of the
- 36 effect is known and appropriately modeled or unknown a semiparametric approach. Future
- 37 research should further examine the dynamics of immunity waning and boosting for more
- 38 reliable inference.

It is made available under a CC-BY-NC 4.0 International license .

## 39 **1. Introduction**

Correlates of protection (COP) are measurable quantities such as binding or neutralizing 40 41 antibody concentrations that predict the degree of protection against incidence of an infectious disease. These markers provide valuable insights into the immune system's response to 42 pathogens and vaccines,<sup>1</sup> which is essential for advancing the understanding of immune 43 44 mechanisms, as well as facilitating estimates of levels of protection in the population over time 45 and informing the evaluation of new vaccines. For example, hemagglutination-inhibition antibody titers have been identified as a COP for influenza.<sup>2,3</sup> COP are particularly useful for 46 estimating vaccine effectiveness by linking the magnitude of an immune response to levels of 47 protection, especially in scenarios where direct measures of effectiveness are not available.<sup>4,5</sup> 48 49 Recent studies highlight the importance of post-immunization antibody titers as effective COP for COVID-19 vaccines.<sup>6,7</sup> Notable research efforts have investigated the use of these 50 51 correlates to forecast absolute risks (AR) and relative risks (RR) of infection in randomized vaccine efficacy trials,<sup>4,6,8–10</sup> using the antibody concentration measured at a fixed time post-52 vaccination. More recently, an observational study using a test-negative design (TND) was 53 54 employed to estimate "exposure-proximal" COP, that is, how the COP level around the time an individual may be exposed to infection affects their risk of becoming infected.<sup>11,12</sup> 55 56 The use of the TND for exposure-proximal COP studies builds on a longstanding tradition of using these studies, which compare vaccination histories of those who test positive 57 for a condition (e.g., COVID-19) with those experiencing the same symptoms but testing 58 negative for the condition, to evaluate vaccine effectiveness. If the vaccine provides all-or-59 60 nothing protection and there are no unmeasured confounding with respect to infection or test-61 seeking, such as due to heterogeneous vaccination decisions or characteristics leading to varying

It is made available under a CC-BY-NC 4.0 International license .

susceptibility among participants, the odds ratio (OR) for vaccination among test-positive vs.
test-negative participants in a TND is an unbiased estimator of the incidence rate ratio (IRR) in
the population, such that one minus the OR estimates vaccine effectiveness (1-IRR). These
assumptions are strong,<sup>13</sup> and methodological work has highlighted that they may be violated in
practice.<sup>14-20</sup>
However, to our knowledge, no study has yet evaluated the validity of the TND for

67 monitoring the relationship between a continuous exposure-proximate COP and protection. In 68 contrast with using the TND for vaccine effectiveness, the goal is not to estimate the causal 69 effect, as interventions on the correlate may not be well defined, but rather to estimate the 70 (predictive) relationship between COP-level and infection over time. In this case, our main 72 concern is the potential for selection bias due to the sampling scheme of the TND.

73 Here, we introduce a novel, simplified simulation model that mimics disease transmission 74 within a community, taking into account vaccination and the waning immunity from previous 75 infections, to explore whether the TND is able to recover the relationship between COP and 76 infection and to identify the correct transformations and statistical models for accurately linking 77 COP to infection. We are specifically interested in situations where assessing vaccine 78 effectiveness in TND may otherwise introduce bias such as when the vaccine exhibits leaky 79 protection. When the relationship between COP, the predictor, and infection risk is linear, we 80 show that a model linking the ln(IRR) of infection to either the logarithm of one minus the 81 linear predictor of incidence rate (parametric) or a flexible function of that predictor 82 (semiparametric) can effectively recover the correct relationship between that predictor and the 83 incidence rate ratio of infection. When the relationship is unknown, we show semiparametric 84 methods are superior.

It is made available under a CC-BY-NC 4.0 International license .

### 85 **2. Methods**

### 86 2.1 Simulation model and assumptions

87 We employed an individual-based transmission model, involving susceptible, exposed,

88 asymptomatically infectious, symptomatically infectious, vaccinated, and recovered individuals,

89 to simulate disease transmission within a community (Figure 1), with detailed parameters listed

90 in **Table 1**. Individuals were tracked because each individual had a level of a scalar measure of

91 immunity, denoted as *X*, that varied over time and affected their risk of becoming infected. The

92 model made several key assumptions: The risk of infection decreases linearly as the individual's

93 COP level increases, calculated as  $\beta * (1 - X) * (1 + A)/N$ , where  $\beta$  is the transmission

94 coefficient, *X* is a rescaled COP level ranging from 0 to 1, *I* is the number of symptomatically

95 infectious individuals, A is the number of asymptomatically infectious individuals, and N is the

96 total population. One third of the infectious individuals are assumed to be symptomatic and this

97 proportion did not vary over time or across subgroups.<sup>21</sup> We assume COP provides equal

98 protection against asymptomatic and symptomatic infection. Individuals cannot receive

99 vaccinations if they are symptomatically infectious. All susceptible individuals start with a COP

100 level at 0 units, and a first-time exposure, including recovery after infection or vaccination, will

raise the COP level from 0.00 to 0.75 units. With subsequent exposures, this level will boost

102 from current level to 1 unit. These specific values act as simplified indicators to assess the degree

103 of protection conferred against infections following the first<sup>22,23</sup> and subsequent<sup>24-26</sup> exposures,

respectively. Additionally, all uninfected individuals experience a linear immunity decline at a
rate of 0.01 units per day, modeled as a simplified waning mechanism, whereas exposed and

106 infectious individuals will remain their antibody level unchanged until they recover.<sup>27–30</sup> Data on

107 each individual's antibody level and infection status is recorded on predetermined simulation

It is made available under a CC-BY-NC 4.0 International license .

- 108 dates. In the simulation, 0.5% of the eligible population will be vaccinated every 15 days from
- 109 day 1 to day 600, totaling 40 rounds. By the end, 20% of the eligible population will receive the
- 110 vaccine.
- 111



112

- 113 Figure 1. Schematic representation of the model<sup>a</sup>
- <sup>a</sup> For detailed descriptions of the parameters used, refer to **Table 1**.
- 115 **State**: S, Susceptible; E, Exposed; I, Symptomatically Infectious; A, Asymptomatically
- 116 Infectious; R, Recovered; V, Vaccinated.
- 117 Arrow: Solid arrows represent continuous transitions between states; dashed arrows represent
- 118 the discrete vaccination schedule as detailed in Methods.
- 119

It is made available under a CC-BY-NC 4.0 International license .

### 120 Table 1. Model parameters

Parameter	Description	Value
N	Population size	50,000
tlatent	Latent period	5 <sup>31</sup>
tinfectious	Infectious period	7 <sup>32</sup>
α	Symptomatically infectious proportion	1/3 <sup>21</sup>
σ	Rate from exposed to infectious	1 / t <sub>latent</sub>
γ	Rate from infectious to recovered	1 / tinfectious
Ro	Basic reproduction number	2 <sup>33</sup>
β	Transmission coefficient	$R_0 / t_{infectious}$
λ	Per capita rate of infection	$\beta$ * no. of infectious people
W	Antibody level waning rate	0.01
Initial S	No. of initial susceptible cases	48,950
Initial E	No. of initial exposed cases	25
Initial I	No. of initial infectious cases	25
Initial R	No. of initial recovered cases	1000

121

# 122 **2.2 Data sampling scheme**

In our simulation, we implemented a data sampling scheme modeled after a typical TND study.<sup>34</sup>
Symptomatically infectious individuals were identified as cases, and each case was matched with
four controls who were susceptible, recovered, or exposed. This sampling scheme implies
selection of controls is independent of COP level on that day. It was assumed that all
symptomatically infectious individuals tested positive, and the matched controls tested negative.

It is made available under a CC-BY-NC 4.0 International license .

128 To increase sample size by aggregating data across multiple days, we used an incidence density 129 sampling approach, matching cases and controls based on the day of sampling. 130 **2.3 Statistical analysis** 131 Our analysis considered four regression models: two logistic regression models (with and without transformation of the independent variable, the COP measurement X) and two 132 133 generalized additive models (GAMs, with and without transformation of X). COP levels were assessed at the time of sampling, reflecting the exposure-proximate COP — the levels measured 134 135 when individuals tested positive or negative. Untransformed models modeled *logit*  $(p) \sim X$  for logistic regression and 136 *logit* (*p*) ~ *GAM*(*X*) for the GAM, while transformed models considered *logit* (*p*) ~ ln(1 - X)137 for the transformed logistic regression and logit  $(p) \sim GAM(ln(1 - X))$  for the transformed 138 139 GAM. The rationale for the transformation was as follows: The transformation applied to these 140 levels was the natural logarithm of 1 - COP level, ln(1 - x), which is used to reflect the log of 141 IRR expression in our model setting when comparing the infection incidence rate at a specific 142 COP level to the rate at zero COP level. The derivation is as follows:  $ln(IRR) = ln\{\lambda * I(t) * I(t) \}$ 143  $U(t) * (1 - X_{X=x}) / [\lambda * I(t) * U(t) * (1 - X_{X=0})] = ln(1 - x)$  where  $\lambda$  is the force of 144 infection, I(t) is the number of infectious individuals at time t, and U(t) is the number of 145 uninfected individuals at time t. Following the logic of TND vaccine studies, in which the OR 146 provides an unbiased estimate of the IRR of infection among vaccinated versus unvaccinated individuals,<sup>13</sup> we posited that the log of IRR is linearly related to the log OR comparing 147 148 individuals with a given level of COP to those who have a COP value of zero and hence the log 149 odds.

It is made available under a CC-BY-NC 4.0 International license .

150	Further, the two different infection risk functions—squared ( $risk = \beta * (1 - X^2) * I/N$ )
151	and cubic ( <i>risk</i> = $\beta * (1 - X^3) * I/N$ ) transformations of the COP level—were sensitivity
152	analyses used to assess the robustness of the approach to estimating the shape of the relationship
153	between the COP value and incidence when the relationship is more complex and nonlinear. <sup>35,36</sup>
154	For each of the parametric and semiparametric methods, three models are applied: an
155	untransformed misspecified model, a transformed misspecified model, and a transformed
156	correctly specified model. In both the misspecified and correctly specified transformed models, a
157	natural logarithmic transformation is used. The misspecified transformed models apply linear
158	COP levels, consistent with the primary analysis, while the correctly specified models use
159	squared and cubic COP levels to align with the corresponding infection risk functions.
160	3. Results
161	The model simulated the spread of infection over 600 days within a community of 50,000
162	individuals. Figure 2 shows the temporal dynamics of infectious-and-symptomatic prevalence,
163	COP level proportions, and odds of infection stratified by COP levels. Four complete waves of
164	infection occurred. Notably, declines in the number of individuals with higher antibody levels,
165	due to waning immunity, preceded the emergence of subsequent infection waves. As expected,
166	the simulation shows lower mean and variability in infection odds and lower amplitudes among
167	those with higher COP levels.
168	

It is made available under a CC-BY-NC 4.0 International license .



169

# Figure 2. Trends in infectious prevalence, COP proportions, and odds of infection<sup>a</sup> from simulation days 10 to 600 with an increment of 10

<sup>a</sup> The odds of infection curves are fitted using cubic splines with 15 degrees of freedom.

173 **Panel A**: the prevalence of infectious individuals. **Panel B**: the distribution of the population

across different antibody intervals. **Panel C**: the odds of incident infection by COP intervals.

175

176 TND sampling from the simulation showed that when using data collected from a single 177 day, the transformed logistic model accurately recovered the linear relationship between COP 178 level and IRR. In contrast, the untransformed logistic model failed to do so due to misspecification of the functional form (Figure 3). Although both semiparametric GAM models 179 generally captured the relationship, they often deviated from the true pattern, particularly at 180 181 extreme COP values (Figure 3A). Figure 3B illustrates the relationships predicted by these 182 models using compiled incidence density data sampled over multiple days, showing that both GAM models produced results more closely aligned with those of the transformed logistic 183 184 model.

185

It is made available under a CC-BY-NC 4.0 International license .



Figure 3. COP level and infection incidence rate ratio sampling on a single simulation day
and compiled simulation days
Panel A used data collected from simulation day 600, panel B used data from simulation days

190 500-600 with an increment of 10.

191

186

192 The impact of population-level antibody distribution and the aggregation of data from 193 multiple days on the accuracy of regression models in predicting infection IRR were 194 investigated. Besides the transformed logistic regression, both GAMs accurately estimate the 195 IRR when sufficient data are aggregated from multiple days using incidence-density sampling 196 (Figure 4D). This accuracy is achieved during periods when the pandemic has stabilized after an extended onset, resulting in a diverse and adequately distributed range of COP levels. In 197 198 situations with more limited numbers of participants with certain COP levels (Figure 4A, C) or 199 insufficient data (Figure 4A, B) from TND sampling, semiparametric approaches tend to 200 produce more complex estimated relationships, likely due to overfitting the noise in the data. In contrast, the transformed logistic regression consistently recovers the linear relationship. 201

202

It is made available under a CC-BY-NC 4.0 International license .



# Figure 4. Impact of antibody distribution<sup>a</sup> and data aggregation on infection incidence rate ratio predictions by regression models

<sup>a</sup> Gray areas in the plots indicate the proportions of COP levels within the population.

207 Panel A used data collected from simulation day 50, panel B used data collected from

simulation day 450, **panel C** used data from simulation days 50-150 with an increment of 10,

and **panel D** used data from simulation days 400-500 with an increment of 10.

210

211 The sensitivity analyses examined the predictability of models on the nonlinear

relationships between infection risk and COP levels, including squared and cubic, with sufficient

213 data sampled. The curves generated from the correctly specified transformed logistic regression

214 models are capturing the true relationships, as the primary analysis did, which further shows the

- 215 robustness of the model selection and transformation function. Although the semiparametric
- 216 models (whether transformed, correctly specified, or not) did not capture the exact relationship at

all levels of COP, they closely approximate the true relationship with only slight fluctuations







#### Figure 5. Sensitivity Analysis – COP level and infection incidence rate ratio sampling on compiled simulation days 500 to 600 with an increment of 10

- 223 Panel A used data from simulation where infection risk correlates with squared COP level, and
- 224 **panel B** used data from simulation where infection risk correlates with cubic COP level.
- 225 Formulas used for **Panel A** include:
- 226 Untransformed Misspecified Logit:  $logit(p) \sim X$
- 227 Transformed Misspecified Logit:  $logit(p) \sim ln(1 X)$
- 228 Transformed Logit:  $logit(p) \sim ln(1 X^2)$
- 229 Untransformed Misspecified GAM:  $logit(p) \sim GAM(X)$
- 230 Transformed Misspecified GAM:  $logit(p) \sim GAM(1 X)$
- 231 Transformed GAM:  $logit(p) \sim GAM(1 X^2)$
- 232

### 233 **4. Discussion**

Antibody levels have been used in prior studies to predict the infection risk of influenza and

- 235 COVID-19, and are considered one of the appropriate COP for investigating the relationship
- between infection and individual immunity. However, apart from one recent paper designed for
- cohort studies,<sup>11</sup> there has been little work to define approaches for estimating exposure-
- 238 proximate COP, that is how an individual's instantaneously measured level of immunity predicts
- their susceptibility to infection at that moment. While prospective cohorts have many
- advantages, case-control designs such as the TND are widely employed due to their

It is made available under a CC-BY-NC 4.0 International license .

comparatively low cost and feasibility. Thus, we sought to understand the conditions under
which a TND would validly estimate the relationship between a COP level and the degree of
protection offered by that level.

244 Our study demonstrates that a TND-style approach can identify the shape of a predictive 245 relationship between a correlate of protection measured near the time of exposure and the risk of 246 infection when using a semiparametric model or when using a correctly specified parametric 247 model with appropriate transformation of the value of the correlate. We have phrased this in 248 terms of prediction rather than causal inference because it is difficult to envision even a 249 hypothetical intervention that would set an individual's COP value at a certain level, and because for many practical purposes, prediction is the question of interest: how well protected is an 250 251 individual, given a particular COP value? In a causal setting one would also have to consider 252 confounding in which a predictor of COP value had a causal effect on the likelihood of infection. 253 For example, if occupation were predictive of vaccination (and thus COP level) and outcome, or 254 in vaccine campaigns where elderly or immunocompromised individuals are prioritized for early 255 uptake and exhibit lower protection at the same COP value. We have used a model in which such 256 common causes do not exist.

Borrowing from the theory of TNDs, the OR estimates the IRR for a particular covariate value. In the simulation, we define the risk of infection as one minus the immunity level. Therefore, in a logistic regression framework, the right-hand side, ln(IRR) or ln(1 - COP), should estimate the left-hand side ln(odds), and our simulations confirm that using this functional form produces estimates that are indistinguishable from the input to the simulation. Alternatively, using a generalized additive model can approximate this relationship if one does not know the proper functional form for the relationship of the COP value to the IRR.

It is made available under a CC-BY-NC 4.0 International license .

264 In TND, estimating the 'vaccine direct effect' for leaky vaccines—those that confer only 265 partial protection to all recipients—is problematic and tends to show declining protection over 266 time. The bias arises because vaccinated individuals continue to experience infections at a 267 reduced rate, while unvaccinated individuals may gain immunity through natural infection.<sup>13</sup> 268 Over time, this dynamic narrows the infection rate gap between vaccinated and unvaccinated 269 groups, causing the OR to trend toward the null. This pattern fails to accurately reflect the 270 vaccine's true effectiveness. In contrast, this study shows that examining immunity levels as a 271 predictor of infection incidence rate does not suffer from this bias. By analyzing infection rate at 272 varying levels of COP, this approach measures how immunity, regardless of its source, 273 influences infection likelihood. Since it does not rely solely on vaccination status, using COP 274 levels sidesteps the specific biases introduced by leaky vaccine effects in TND. This method, 275 therefore, offers a framework for understanding how incremental COP levels may influence 276 infection incidence rates, while minimizing the impact of vaccine-specific assumptions. 277 The utilization of simulation models stands out as a major strength of this study, allowing 278 us to emulate real-life pandemic scenarios with a degree of control over experimental variables 279 and pre-assumed infection relative risk functions that are not typically possible in field studies. 280 This approach enabled us to systematically test different infection IRR functions, both linear and 281 nonlinear, and to assess their impact on the relationship between immunity levels and infection 282 risks. Additionally, by employing several logistic regression models on the results obtained from 283 TND, we have enhanced the robustness and applicability of our findings to actual pandemic 284 conditions. Despite its strengths, our study is not without limitations. The infection IRR and risk 285 functions used were intentionally simplified, which might have affected the granularity and 286 generalizability of our findings. Similarly, the model simplifies assumptions about immunity

It is made available under a CC-BY-NC 4.0 International license .

287	boosting and waning, which may not fully capture the complexities of immunity development
288	and decline in diverse populations. Prior studies suggest that immunity waning could be
289	nonlinear, <sup>35,36</sup> indicating that the model might overlook important variations. Furthermore, the
290	assumption of homogeneity among agents-considering them to have identical susceptibility and
291	transmission characteristics—may not truly reflect the variability observed in real populations. <sup>37</sup>
292	Future research should aim to incorporate more realistic infection IRR and risk functions
293	and more sophisticated mechanisms for modeling immunity waning and boosting. Additionally,
294	enhancing the model by calibrating it with real-world data that includes detailed agent
295	characteristics and distributions of COP among circulating variants of concern could
296	significantly improve the model's accuracy and relevance. Such advancements are important for
297	developing more effective epidemiological models, which, in turn, can inform public health
298	strategies and vaccination programs more accurately.
299	5. Conclusion

300 Antibody levels are vital in epidemiological research, serving as a key metric for evaluating how 301 these COP are associated with infections under various study designs. These insights are crucial for assessing vaccine efficacy and guiding public health interventions. This study shows that 302 303 employing logistic regression models with natural logarithm transformations of infection IRR 304 function helps to model the relationship between infection incidence rate and antibody levels 305 more precisely, enabling the visualization of both linear and nonlinear effects. To enhance model 306 accuracy, it is essential to refine infection IRR and risk functions and integrate mechanisms of 307 immunity waning and boosting given vaccination or infection within these models. Calibration 308 with real-world data is crucial to confirm model accuracy and relevance. By transitioning from 309 basic theoretical frameworks to more sophisticated, data-driven models, researchers can more

It is made available under a CC-BY-NC 4.0 International license .

- 310 effectively simulate the complex interplay between pathogen exposure, immune response, and
- 311 population health outcomes, advancing the understanding of immunity dynamics and improving
- 312 the capacity to predict and manage infectious diseases.

It is made available under a CC-BY-NC 4.0 International license .

#### 313 References

- Plotkin SA. Correlates of Protection Induced by Vaccination. *Clin Vaccine Immunol*.
   2010;17(7):1055-1065. doi:10.1128/CVI.00131-10
- Black S, Nicolay U, Vesikari T, et al. Hemagglutination Inhibition Antibody Titers as a
   Correlate of Protection for Inactivated Influenza Vaccines in Children. *Pediatr Infect Dis J*.
   2011;30(12):1081-1085. doi:10.1097/INF.0b013e3182367662
- Ohmit SE, Petrie JG, Cross RT, Johnson E, Monto AS. Influenza Hemagglutination-Inhibition Antibody Titer as a Correlate of Vaccine-Induced Protection. *J Infect Dis*. 2011;204(12):1879-1885. doi:10.1093/infdis/jir661
- 4. Earle KA, Ambrosino DM, Fiore-Gartland A, et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. *Vaccine*. 2021;39(32):4423-4428.
   doi:10.1016/j.vaccine.2021.05.063
- 5. Khoury DS, Schlub TE, Cromer D, et al. Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infection. *Emerg Infect Dis*.
  2023;29(2):381-388. doi:10.3201/eid2902.221422
- Gilbert PB, Montefiori DC, McDermott AB, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. *Science*. 2022;375(6576):43-50. doi:10.1126/science.abm3425
- Dimeglio C, Herin F, Martin-Blondel G, Miedougé M, Izopet J. Antibody titers and protection against a SARS-CoV-2 infection. *J Infect*. 2022;84(2):248-288.
   doi:10.1016/j.jinf.2021.09.013
- Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. *Nat Med.* 2021;27(11):2032-2040.
   doi:10.1038/s41591-021-01540-1
- 337 9. Goldblatt D, Fiore-Gartland A, Johnson M, et al. Towards a population-based threshold of
  338 protection for COVID-19 vaccines. *Vaccine*. 2022;40(2):306-315.
  339 doi:10.1016/j.vaccine.2021.12.006
- 10. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive
  of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med.*2021;27(7):1205-1211. doi:10.1038/s41591-021-01377-8
- 11. Nilles EJ, Paulino CT, de St Aubin M, et al. Tracking immune correlates of protection for
  emerging SARS-CoV-2 variants. *Lancet Infect Dis*. 2023;23(2):153-154.
  doi:10.1016/S1473-3099(23)00001-4
- Huang Y, Follmann D. Exposure proximal immune correlates analysis. *Biostatistics*.
  Published online August 14, 2024:kxae031. doi:10.1093/biostatistics/kxae031

- 13. Lewnard JA, Tedijanto C, Cowling BJ, Lipsitch M. Measurement of Vaccine Direct Effects
  Under the Test-Negative Design. *Am J Epidemiol*. 2018;187(12):2686-2697.
  doi:10.1093/aje/kwy163
- 14. Endo A, Funk S, Kucharski AJ. Bias correction methods for test-negative designs in the
  presence of misclassification. *Epidemiol Infect*. 2020;148:e216.
  doi:10.1017/S0950268820002058
- 354 15. Jackson ML, Rothman KJ. Effects of imperfect test sensitivity and specificity on
  355 observational studies of influenza vaccine effectiveness. *Vaccine*. 2015;33(11):1313-1316.
  356 doi:10.1016/j.vaccine.2015.01.069
- 16. De Smedt T, Merrall E, Macina D, Perez-Vilar S, Andrews N, Bollaerts K. Bias due to
  differential and non-differential disease- and exposure misclassification in studies of vaccine
  effectiveness. Hozbor DF, ed. *PLOS ONE*. 2018;13(6):e0199180.
  doi:10.1371/journal.pone.0199180
- 17. Lipsitch M, Jha A, Simonsen L. Observational studies and the difficult quest for causality:
   lessons from vaccine effectiveness and impact studies. *Int J Epidemiol*. Published online July
   24, 2016:dyw124. doi:10.1093/ije/dyw124
- 364 18. Sullivan SG, Tchetgen Tchetgen EJ, Cowling BJ. Theoretical Basis of the Test-Negative
  365 Study Design for Assessment of Influenza Vaccine Effectiveness. *Am J Epidemiol*.
  366 2016;184(5):345-353. doi:10.1093/aje/kww064
- 367 19. Westreich D, Hudgens MG. Invited Commentary: Beware the Test-Negative Design. *Am J Epidemiol.* 2016;184(5):354-356. doi:10.1093/aje/kww063
- 20. Chua H, Feng S, Lewnard JA, et al. The Use of Test-negative Controls to Monitor Vaccine
   Effectiveness: A Systematic Review of Methodology. *Epidemiology*. 2020;31(1):43-64.
   doi:10.1097/EDE.00000000001116
- 372 21. Oran DP, Topol EJ. The Proportion of SARS-CoV-2 Infections That Are Asymptomatic: A
  373 Systematic Review. *Ann Intern Med.* 2021;174(5):655-662. doi:10.7326/M20-6976
- Kojima N, Klausner JD. Protective immunity after recovery from SARS-CoV-2 infection.
   *Lancet Infect Dis*. 2022;22(1):12-14. doi:10.1016/S1473-3099(21)00676-9
- Wang Z, Muecksch F, Schaefer-Babajew D, et al. Naturally enhanced neutralizing breadth
  against SARS-CoV-2 one year after infection. *Nature*. 2021;595(7867):426-431.
  doi:10.1038/s41586-021-03696-9
- 379 24. Hall V, Foulkes S, Insalata F, et al. Protection against SARS-CoV-2 after Covid-19
  380 Vaccination and Previous Infection. *N Engl J Med.* 2022;386(13):1207-1220.
  381 doi:10.1056/NEJMoa2118691

- 382 25. Glück V, Grobecker S, Köstler J, et al. Immunity after COVID-19 and vaccination: follow383 up study over 1 year among medical personnel. *Infection*. 2022;50(2):439-446.
  384 doi:10.1007/s15010-021-01703-9
- 26. Abbasi J. Study Suggests Lasting Immunity After COVID-19, With a Big Boost From
   Vaccination. *JAMA*. 2021;326(5):376. doi:10.1001/jama.2021.11717
- 387 27. Goldberg Y, Mandel M, Bar-On YM, et al. Protection and Waning of Natural and Hybrid
  388 Immunity to SARS-CoV-2. *N Engl J Med.* 2022;386(23):2201-2212.
  389 doi:10.1056/NEJMoa2118946
- 28. Andrews N, Tessier E, Stowe J, et al. Duration of Protection against Mild and Severe
  Disease by Covid-19 Vaccines. *N Engl J Med.* 2022;386(4):340-350.
  doi:10.1056/NEJMoa2115481
- 393 29. Goldberg Y, Mandel M, Bar-On YM, et al. Waning Immunity after the BNT162b2 Vaccine
  394 in Israel. *N Engl J Med*. 2021;385(24). doi:10.1056/NEJMoa2114228
- 30. Ferdinands JM, Rao S, Dixon BE, et al. Waning 2-Dose and 3-Dose Effectiveness of mRNA
  Vaccines Against COVID-19–Associated Emergency Department and Urgent Care
  Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron
  Variant Predominance VISION Network, 10 States, August 2021–January 2022. MMWR
  Morb Mortal Wkly Rep. 2022;71(7):255-263. doi:10.15585/mmwr.mm7107e2
- 31. Xin H, Li Y, Wu P, et al. Estimating the Latent Period of Coronavirus Disease 2019
  (COVID-19). *Clin Infect Dis*. 2022;74(9):1678-1681. doi:10.1093/cid/ciab746
- 32. Ma S, Zhang J, Zeng M, et al. Epidemiological parameters of coronavirus disease 2019: a
  pooled analysis of publicly reported individual data of 1155 cases from seven countries.
  Published online March 24, 2020. doi:10.1101/2020.03.21.20040329
- 33. Locatelli I, Trächsel B, Rousson V. Estimating the basic reproduction number for COVID-19
  in Western Europe. Khudyakov YE, ed. *PLOS ONE*. 2021;16(3):e0248731.
  doi:10.1371/journal.pone.0248731
- 408 34. Feldstein LR, Self WH, Ferdinands JM, et al. Incorporating Real-time Influenza Detection
  409 Into the Test-negative Design for Estimating Influenza Vaccine Effectiveness: The Real-time
  410 Test-negative Design (rtTND). *Clin Infect Dis*. 2021;72(9):1669-1675.
  411 doi:10.1093/cid/ciaa1453
- 412 35. Pérez-Alós L, Armenteros JJA, Madsen JR, et al. Modeling of waning immunity after SARS413 CoV-2 vaccination and influencing factors. *Nat Commun.* 2022;13(1):1614.
- 414 doi:10.1038/s41467-022-29225-4
- 36. Ghosh SK, Ghosh S. A mathematical model for COVID-19 considering waning immunity,
  vaccination and control measures. *Sci Rep.* 2023;13(1):3610. doi:10.1038/s41598-02330800-y

It is made available under a CC-BY-NC 4.0 International license .

- 418 37. Bushman M, Kahn R, Taylor BP, Lipsitch M, Hanage WP. Population impact of SARS-
- 419 CoV-2 variants with enhanced transmissibility and/or partial immune escape. *Cell*.
- 420 2021;184(26):6229-6242.e18. doi:10.1016/j.cell.2021.11.026

421